Baseline CD4<sup>+</sup> and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients-Reference-Cited by-同舟云学术

Baseline CD4⁺ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients

Published:2024-04 Issue:4 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Massa Chiara¹²^ORCID,Karn Thomas³,Weber Karsten⁴,Schneeweiss Andreas⁵,Hanusch Claus⁶,Uwe Blohmer Jens⁷,Zahm Dirk‐Michael⁸,Jackisch Christian⁹,Mackelenbergh Marion van¹⁰,Thomalla Jörg¹¹,Marmé Frederik¹²,Huober Jens¹³,Müller Volkmar¹⁴,Schem Christian¹⁵,Müller Anja¹,Stickeler Elmar¹⁶,Biehl Katharina¹,Fasching Peter A.¹⁷,Untch Michael¹⁸,Loibl Sibylle⁴,Denkert Carsten¹⁹,Seliger Barbara¹²

Affiliation:

1. Institute of Medical Immunology Martin Luther University Halle‐Wittenberg Halle Germany

2. Institute for Translational Immunology Brandenburg Medical School Theodor Fontane Brandenburg an der Havel Germany

3. Department of Obstetrics and Gynecology Goethe University Frankfurt Germany

4. German Breast Group, GBG Forschungs GmbH Neu‐Isenburg Germany

5. Nationales Centrum für Tumorerkrankungen Universitätsklinikum und Deutsches Krebsforschungszentrum Heidelberg Germany

6. Rotkreuzklinikum München München Germany

7. Gynäkologie mit Brustzentrum der Charite CCM Charité‐Universitätsmedizin Berlin Berlin Germany

8. SRH Wald‐Klinikum Gera Gera Germany

9. Department of Obstetrics and Gynecology Sana Klinikum Offenbach Offenbach Germany

10. Klinik für Gynäkologie und Geburtshilfe Universitätsklinikum Schleswig‐Holstein Kiel Germany

11. Praxis für Hämatologie und Onkologie Koblenz Germany

12. Universitätsfrauenklinik Medizinische Fakultät Mannheim der Universität Heidelberg Heidelberg Germany

13. Breast Cancer Cantonal Hospital St.Gallen St. Gallen Switzerland

14. Department of Obstetrics and Gynecology Universitätsklinikum Hamburg‐Eppendorf Hamburg Germany

15. Mammazentrum am Krankenhaus Jerusalem Hamburg Germany

16. Klinik für Gynäkologie und Geburtsmedizin Uniklinik RWTH Aachen Aachen Germany

17. Department of Obstetrics and Gynecology Universitätsklinikum Erlangen Erlangen Germany

18. Department of Obstetrics and Gynecology HELIOS Klinikum Berlin Buch Berlin Germany

19. Institute of Pathology Philipps‐University Marburg and University Hospital Marburg (UKGM) Marburg Germany

Funder

Celgene

Deutsche Krebshilfe

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1617

Reference9 articles.

1. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

2. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies